Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Greten Website

Tim F. Greten, M.D.

Selected Publications

1)  Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF, Korangy F.
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Gastroenterology. 135: 234-43, 2008.
[Journal]
2)  Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F.
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.
Hepatology. 50: 799-807, 2009.
[Journal]
3)  Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F.
Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells.
Blood. 117: 6532-41, 2011.
[Journal]
4)  Gamrekelashvili J, Kapanadze T, Han M, Wissing J, Ma C, Jaensch L, Manns MP, Armstrong T, Jaffee E, White AO, Citrin DE, Korangy F, Greten TF.
Peptidases released by necrotic cells control CD8+ T cell cross-priming.
J. Clin. Invest. 123: 4755-68, 2013.
[Journal]
5)  Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, Zender L, Kapoor V, Felsher DW, Manns MP, Korangy F, Greten TF.
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
J. Hepatol. 59: 1007-13, 2013.
[Journal]
6)  Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc J, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon J, Wendum D, Rosmorduc O, Greten TF.
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Lancet Oncol. [Epub ahead of print], 2014.
[Journal]
7)  Medina-Echeverz J, Haile LA, Zhao F, Gamrekelashvili J, Ma C, Métais J, Dunbar CE, Kapoor V, Manns MP, Korangy F, Greten TF.
IFN-gamma regulates survival and function of tumor-induced CD11b(+) Gr-1(high) myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1.
Eur. J. Immunol. [Epub ahead of print], 2014.
[Journal]
8)  Hato T, Goyal L, Greten TF, Duda DG, Zhu AX.
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions.
Hepatology. [Epub ahead of print], 2014.
[Journal]
9)  Duffy AG, Greten TF.
Immunological off-target effects of standard treatments in gastrointestinal cancers.
Ann. Oncol. 25: 24-32, 2014.
[Journal]
10)  Greten TF.
Myeloid-derived suppressor cells in pancreatic cancer: more than a hidden barrier for antitumour immunity?.
Gut. [Epub ahead of print], 2014.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/18/2014.